Epicardial Ventricular Tachycardia Ablation for Which Patients? by Roten, L. et al.
With an ageing population and widespread use of implantable
cardioverter-defibrillators, physicians are confronted with an
increasing number of patients with symptomatic, drug-refractory
ventricular tachycardia (VT). Catheter ablation is an important
treatment option in the management of patients with structural
heart disease and VT.1,2 In many patients, VT can be successfully
ablated from the endocardium of the left or right ventricle via 
a trans-venous, trans-septal or retrograde trans-arterial access.
However, even in high-volume centres, VT ablation from the
endocardium fails in over one third of patients.3–5 One important
reason for this high failure rate is that VT origin may lie in the
epicardium which is not affected by endocardial ablation with
current techniques.1
In 1996, Sosa first described a technique to obtain percutaneous
access to the pericardial space in three patients with chagasic
cardiomyopathy.6 Epicardial ablation has since been incorporated into
VT ablation strategies by many centres7–10 with its use increasing in
recent years.4 The addition of epicardial mapping and ablation to the
VT ablation strategy in patients with failed, previous endocardial
ablation, increases success rate.7–10 Epicardial access can be obtained
in most patients by experienced operators. Nevertheless, epicardial
mapping and ablation has its risks and the complication rate is higher
than an endocardial approach.11
An important question regarding epicardial VT ablation, and the topic
of this review is ‘in which patient should epicardial access be
considered?’ Timing is important as well – most operators prefer to
gain epicardial access before full anticoagulation is administered.
Therefore, the decision on epicardial access generally has to be made
before left ventricular endocardial ablation.
Several clues can suggest whether important epicardial substrate will 
be present in a given patient, and these will be discussed in the 
following sections. Some of these clues, like the type of cardiomyopathy
and 12-lead electrocardiogram (ECG) of VT, are available before a 
first procedure; while intra-procedural findings, like electrogram
characteristics and results of endocardial mapping, may help to define
the strategy of future procedures in case of failure. In some instances,
epicardial access is contra-indicated or, conversely, the only available
option to ablate VT; this will be discussed in the last section. 
Electrocardiogram and Electrogram
Characteristics Predicting Epicardial 
Origin of Ventricular Tachycardia 
Several groups have investigated the value of the 12-lead ECG of VT
or electrogram characteristics for prediction of epicardial VT origin
(see Tables 1 and 2). 
Electrocardiogram Characteristics of 
Ventricular Tachycardia
Berruezo et al. included patients with heart disease and VT with right
bundle branch block morphology, and compared VT successfully
ablated from the endocardium, with VT either successfully ablated from
the epicardium or not successfully ablated from the endocardium.12 A
pseudo-delta wave ≥34 ms, an intrinsicoid deflection time in V2 ≥85 ms
and a shortest precordial RS complex duration ≥121 ms all suggested
an epicardial origin of VT (see Tables 1 and 2). Later studies confirmed
that these criteria are useful for distinguishing an epicardial origin for
left ventricular VT, but sensitivity and specificity of the suggested cut off
values were lower when applied to select areas of the left ventricle.13,14
Another study compared epicardial with endocardial paced beats and
showed that these criteria did not apply to the right ventricle.15
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Daniels et al. reported on patients with idiopathic VT arising from 
the left epicardium, remote from the aortic sinus of Valsalva.6
Compared to the remaining patients with idiopathic VT, a maximum
deflection index ≥0.55 identified patients with VT of epicardial origin
(see Tables 1 and 2). Bazan et al. compared ECG features of paced
beats at endocardial and epicardial right ventricular sites in a 
mixed population with and without structural heart disease.15 They
found that a stimulus arising from the anterior right ventricular
epicardium presents with a Q wave or QS complex in lead I and 
V2, respectively, and that a stimulus arising from the inferior right
ventricular epicardium shows an initial Q wave in the inferior 
leads (see Table 2). In another study on 15 patients without prior
myocardial infarction, the same group investigated QRS morphology
during endocardial and epicardial left ventricular pace mapping and
looked at QRS morphology of 19 epicardial VT.13 Site-specific
morphology criteria that identified an epicardial origin were a Q wave
in lead I for basal superior and apical superior sites, the absence of 
a Q wave in any of the inferior leads for basal superior sites, and a 
Q wave in inferior leads for basal inferior and apical inferior sites.
Their proposed morphology criteria correctly identified epicardial
origin in 84 % of VT (see Table 2). Vallès et al. tested most of the
above-mentioned criteria in 14 patients with non-ischaemic
cardiomyopathy, comparing endocardial and epicardial pace maps at
basal superior to lateral sites in the left ventricle.14 They applied these
criteria to VT mapped from the same region. Of all published criteria,
the morphology criteria (presence of a Q wave in lead I and absence
of Q waves in the inferior leads) were the most specific for both
epicardial pace mapping and epicardial VT origin. The presence of a
Q wave in lead I was also a very sensitive criterion (see Table 2). All
interval criteria had modest specificity. They proposed a 4-step
algorithm, including two morphology criteria and two interval criteria,
with modified cut-offs. This algorithm, when applied to a validation
cohort, had high specificity and sensitivity in determining epicardial
versus endocardial VT origin in patients with non-ischaemic
cardiomyopathy and VT from basal superior to lateral origin.14
The value of QRS duration in differentiating endocardial from
epicardial origin has also been investigated in these studies. It was
reported to be significantly longer in left ventricular VT of epicardial
compared to endocardial origin12,14 and in epicardial compared to
endocardial pace mapping.13,14 However, because of considerable
overlap between groups, QRS duration was not able to differentiate
epicardial from endocardial VT origin. On the other hand, QRS
duration was not different in epicardial compared to endocardial
idiopathic VT arising remote from the aortic sinus of Valsalva16 and in
epicardial versus endocardial right ventricular pace mapping.15 The
latter may be explained by the thinner right ventricular myocardium
and less extensive Purkinje network in the right ventricle. 
In summary, although some ECG criteria suggest an epicardial 
VT origin, other factors significantly influence their validity; 
most importantly the type of cardiomyopathy and region of VT
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IDT = Intrinsicoid deflection time; MDI = Maximum deflection index; QRSd = QRS duration.
For explanation of interval criteria see Table 1. Adapted with permission from Valles et al.14
Figure 1: 12-lead Electrocardiogram of a Ventricular
Tachycardia Demonstrating Interval and 
Morphology Criteria 
I
II
III
I
II
III
aVR
aVL
Absence of q wave
Presence of q wave
IDT: 112 ms
QRSd: 206 ms
Pseudo-delta wave: 56 ms
MDI: 103 ms/206 ms: 0.5
Shortest RS complex: 157 ms
100 ms
aVF
V1
V2
V3
V4
V5
V6
Table 1: Proposed Electrocardiogram Criteria and Cut-offs for Epicardial Ventricular Tachycardia Origin 
ECG criteria                               Abbreviation       Explanation                                                                                                                                       Cut-off
Interval criteria
QRS duration                                QRSd                     Interval measured from the earliest ventricular activation to the offset of the QRS in the                    No cut-off  
                                                                                  precordial leads.                                                                                                                                         proposed
Pseudo-delta wave                      PdW                      Interval measured from the earliest ventricular activation to the onset of the earliest fast                  ≥34 ms
                                                                                  deflection in any precordial lead
Intrinsicoid deflection time          IDT                        Interval measured from the earliest ventricular activation to the peak of the R wave in lead V2           ≥85 ms
Shortest RS complex                    SRS                       Interval measured from the earliest ventricular activation to the nadir of the first S wave                    ≥121 ms
                                                                                  in any precordial lead
Maximum deflection index          MDI                       Interval measured from the earliest ventricular activation to the peak of the largest amplitude           ≥55
                                                                                  deflection in each precordial lead (taking the lead with shortest time) divided by the QRSd
Morphology criteria (site-specific) 
Q wave in lead 1                          QWL1                    Q wave in lead 1 during VT                                                                                                                        -
Q wave in inferior leads               QWIL                     Q wave in inferior leads during VT                                                                                                             -
No Q wave in inferior leads         NQWIL                   No Q wave in inferior leads during VT                                                                                                       -
QS in lead V2                                QSV2                     QS complex in lead V2 during VT                                                                                                               -
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origin. These limitations have to be considered when applying the
above-mentioned ECG criteria for assessment of VT origin.
Electrogram Characteristics 
The first clue to an epicardial substrate is the absence of low-voltage
areas or fractionated/abnormal electrograms during sinus rhythm
mapping; i.e. no diseased endocardial tissue. A VT activation map
that shows a pseudo-focal activation pattern with the earliest
endocardial signals barely preceding QRS onset also suggests a
deep sub-endocardial or epicardial substrate. Other important tools
that can help determine the presence of an epicardial substrate are
endocardial unipolar voltage mapping and epicardial mapping
through the coronary venous system.
Two studies by the same group tested the hypothesis that endocardial
unipolar voltage mapping in patients with VT might identify the extent
of epicardial bipolar voltage abnormalities.17,18 In both studies, the
group first defined normal endocardial unipolar electrogram
amplitudes in patients without structural heart disease. For the right
ventricle, 95 % of endocardial unipolar signals had an amplitude
>5.5 mV and defined a normal unipolar electrogram amplitude.18 For
the left ventricle, the corresponding amplitude was >8.27 mV.17 Next,
endocardial and epicardial bipolar voltage maps and endocardial
unipolar voltage maps were generated in patients with mainly
arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D)18
and non-ischaemic cardiomyopathy.17
The ARVC/D patients had limited endocardial bipolar voltage
abnormality, however, the area of unipolar voltage abnormality 
(cut-off <5.5 mV) was more extensive and correlated well with 
the larger area of epicardial bipolar voltage abnormality with respect 
to size and location.18 Importantly, in control patients with normal 
right ventricular endocardial unipolar voltage maps, epicardial bipolar
voltage maps showed no abnormality.18
Table 2: Studies Investigating Electrocardiogram Criteria for Detection of Epicardial Ventricular Tachycardia Origin 
Author      Patients                     Region          Methods          Criteria              Criteria Performance Endo        Criteria Performance        Comments
and Year                                     Assessed                               Assessed           versus Epi Pace Maps                 Endo versus Epi VT
Berruezo   CRT patients (pace     LV                   Pace map         PdV; IDT;             PdV, IDT; SRS and QRSd all           QRSd epi > QRSd endo        67 % of patients  
200412         map) and patients                             endo/epi; VT     SRS; QRSd           significantly longer during epi      PdW: SN 83 %; SP 95 %       had ischemic 
                  with VT of RBBB                                 endo/epi                                       compared to endo pace map       IDT: SN 87 %; SP 90 %         cardiomyopathy
                  morphology                                                                                                                                                    SRS: SN 76 %; SP 85 %
Bazan         Patients undergoing    RV                   Pace map         QRSd; QWL1;      QRSd, PdW, IDT and SRS              -                                            In RVOT and basal 
200615         endo/epi pace                                   endo/epi           QSV2; QWIL;       not different endo vs.                                                                RV no criterion  
                  mapping                                                                       PdW; IDT; SRS     epi pace map                                                                             different endo vs.  
                                                                                                                                   Anterior RV:                                                                               epi pace map; 39 %
                                                                                                                                   QWL1: SN 52 %; SP 94 %                                                           of patients had no 
                                                                                                                                   QSV2: SN 67 %; SP 61 %                                                            structural heart 
                                                                                                                                   Inferior RV:                                                                                 disease
                                                                                                                                   QWIL: SN 71 %; SP 74 %
Daniels       Patients with               LV (endo VT    VT endo/epi      QRSd; MDI           -                                                      QRSd not different endo     All epi VT >1 cm  
200616         idiopathic VT                from RVOT                                                                                                                  vs. epi VT                             away from aortic 
                                                      as well)                                                                                                                       MDI: SN 100%; SP 99 %       sinus of Valsalva 
                                                                                                                                                                                          (no prospective                   and all perivascular
                                                                                                                                                                                          evaluation)
Bazan         Patients undergoing    LV                   Pace map         QRSd; PdV;         QRSd epi > QRSd endo                  PdV, IDT and SRS                No patient had 
200713         endo/epi catheter                              endo/epi;          IDT; SRS;              PdV, IDT and SRS site specific        above cut-off in 74 %,        previous MI; 60 % of
                  mapping and ablation                         VT epi                QWL1; QSV2;      PdW: SN 96 %; SP 29 %                 47 % and 53 % of epi          patients had NICM
                                                                                                       QWIL                    IDT: SN 39 %; SP 24 %                   VT, respectively
                                                                                                                                   SRS: SN 53 %; SP 79 %                  Basal superior LV VT:
                                                                                                                                   Basal superior LV:                        QWL1: 9/10 VT
                                                                                                                                   QWL1: 90 % epi and 16 % endo      QWIL: 0/10 VT
                                                                                                                                   Apical superior LV:
                                                                                                                                   QWL1: 88 % epi and 26 % endo
                                                                                                                                   Basal inferior LV:
                                                                                                                                   QWIL: 81 % epi and 37 % endo
                                                                                                                                   Apical inferior LV:
                                                                                                                                   QWIL: 92 % epi and 33 % endo
Vallès         NICM and VT                Basal              Pace map          QRSd; PdW;        QRSd epi > QRSd endo                  QRSd epi > QRSd endo        4-step ECG 
201014                                             superior to      endo/epi;          IDT; SRS; MDI;     PdW: SN 73 %; SP 63 %                 PdW: SN 62 %; SP 50 %       algorithm proposed
                                                      lateral LV        VT endo/epi       QWLI; NQWIL       IDT: SN 83 %; SP 70 %                   IDT: SN 69 %; SP 50 %         for epi/endo VT  
                                                                                                                                   SRS: SN 74 %; SP 57 %                  SRS : SN 93 % ; SP 50 %      origin: SN 93 % and
                                                                                                                                   MDI: SN 30 %; SP 89 %                  MDI: SN 33 %; SP 75 %        SP 86% in a 
                                                                                                                                   QWL1: SN 91 %; SP 96 %               QWL1: SN 88 %; SP 88 %     validation cohort
                                                                                                                                   NQWIL: SN 99 %; SP 58 %             NQWIL: SN 94 %; SP 63 %
NICM = Non-ischaemic cardiomyopathy
MI = Myocardial infarction
LV = Left ventricle
RV = Right ventricle
VT = Ventricular tachycardia
Endo = Endocardial
Epi = Epicardial
SN = Sensitivity
SP = Specificity
QRSd = QRS duration
PdW = Pseudo-delta wave
IDT = Intrinsicoid deflection time
SRS = Shortest RS complex
MDI = Maximum deflection index
QWL1 = Q wave in lead 1
QWIL = Q wave in inferior leads
NQWIL = No Q wave in inferior leads
QSV2 = QS complex in lead V2
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In patients with non-ischaemic cardiomyopathy and normal
endocardial bipolar voltage maps but epicardial bipolar voltage
abnormality, confluent regions of endocardial unipolar low-voltage
areas (cut-off <8.27 mV) were observed in 82 % of patients, directly
corresponding with areas of epicardial bipolar low voltage (61 %
overlap).17 Control patients with structurally normal hearts and no
epicardial bipolar voltage abnormality had no endocardial unipolar
low voltage areas. Therefore, unipolar endocardial voltage maps can
provide valuable information about the presumed extent of epicardial
substrate, but so far this has only been studied in patients with
ARVC/D and non-ischaemic cardiomyopathy. 
The value of epicardial mapping through the coronary venous system 
in patients with sustained ventricular tachycardia was first described in
1998.19 Reithmann et al. reported their experience with coronary venous
mapping using a micro-electrode catheter in 33 consecutive patients
with structural heart disease admitted for VT ablation.20 Coronary
venous mapping revealed fractionated diastolic electrograms during VT
in 24 % of patients. Endocardial ablation in these patients was
successful in 13 % compared to 72 % of patients in whom no epicardial
diastolic electrograms were mapped during VT. Epicardial ablation was
successfully performed in four of seven patients with unsuccessful
endocardial ablation and diastolic potentials mapped via the coronary
venous system. In summary, the coronary venous system provides 
an easy access to the epicardium. With a micro-electrode catheter a
sizeable portion of the epicardium can be mapped and provide insights
into the presence of an epicardial substrate. 
Epicardial Substrate According to the 
Type of Cardiomyopathy 
The substrate responsible for VT origin varies widely among 
different types of cardiomyopathy. Consequently, the rate by which
successful VT ablation requires epicardial mapping and ablation is
highly dependent on the type of cardiomyopathy. Of all the information
available prior to a first VT ablation procedure, the type of
cardiomyopathy is probably the best predictor for the necessity 
of an epicardial approach and we will discuss this in the next section. 
Table 3 summarises the available data with regard to epicardial
substrate and type of cardiomyopathy. 
Arrhythmogenic Right Ventricular Dysplasia
Attempts at endocardial VT ablation in patients fulfilling taskforce criteria
for ARVC/D were disappointing, with high recurrence rates despite
multiple procedures irrespective of acute procedural success.21 In a
study by Verma et al., arrhythmia-free outcome was somewhat
improved with a substrate-based endocardial ablation strategy, but after
years half the patient experienced arrhythmia recurrence despite
continuing their anti-arrhythmic drug treatment.22 
Histo-pathological studies in the hearts of ARVC/D patients showed
transmural myocardial atrophy with fatty or fibro-fatty infiltration that
was much more extensive on the epicardial side.23 Accordingly,
concomitant endo- and epicardial mapping in ARVC/D patients revealed
a significantly larger epicardial area of electrogram abnormalities.24,25
Different groups have reported high rates of arrhythmia-free outcome
with combined endo- and epicardial substrate ablation in ARVC/D
patients.24–26 Two non-randomised, multicentre studies compared
outcomes of ARVC/D patients treated with combined endo-epicardial
ablation versus exclusive endocardial ablation; both found significantly
higher long-term freedom from recurrent VT in the groups treated with
combined ablation.27,28
Because of the unique pathology of ARVC/D, epicardial scar plays a
major role in VT origin; important parts of re-entry circuits may lie
epicardially in this patient population.23,24 Therefore, if VT ablation 
is contemplated in ARVC/D patients, an epicardial approach may be
considered during the first procedure, following ineffective
endocardial ablation, or following arrhythmia recurrence after an
initially successful endocardial ablation. As discussed above, the
extent of the epicardial substrate in ARVC/D patients may be
identified by endocardial unipolar mapping.18
Dilated Cardiomyopathy
The main mechanism of VT in patients with dilated cardiomyopathy 
is myocardial reentry. Bundle branch re-entry, inter-fascicular 
re-entry and focal automaticity are rarer mechanisms.29,30 While
endocardial ablation of myocardial reentry has a modest success rate, it
is very successful for the remaining tachycardia mechanisms.29,30 Scar
tissue is uniformly present in cases with myocardial re-entry and mostly
Table 3: Presence of Epicardial Substrate and Necessity of Epicardial Ablation According to Type of Cardiomyopathy
Type of Cardiomyopathy        Epicardial Substrate      Epicardial Ablation                                            Comments
ARVC/D                                      Very frequent                  First line or after ineffective endocardial             Histo-pathological studies show more extensive    
                                                                                          ablation/arrhythmia recurrence                            epicardial than endocardial scar tissue
Dilated cardiomyopathy            Frequent                          After ineffective endocardial                                No epicardial ablation necessary in cases with    
                                                                                          ablation/arrhythmia recurrence or may               bundle-brunch-reentry or focal mechanism
                                                                                          be considered first line in selected patients
Myocarditis                                Probably frequent           May have a role, only scarce data                        Inflammation involves mainly mid-wall and sub-epicardium
Chagasic cardiomyopathy        Very Frequent                 May be attempted first line                                   Epicardial scar area larger than endocardial scar area
Hypertrophic                              Probably frequent           May have a role, only small case series               Apical form of hypertrophic cardiomyopathy may more 
cardiomyopathy                                                                                                                                                frequently have epicardial substrate
Brugada syndrome                    Probably frequent           Very effective according to one single study          If frequent ventricular ectopics present endocardial   
                                                                                                                                                                         ablation of ectopics very successful
Sarcoidosis                                Probably frequent           May have a role, only small case series               Predilection of granulomas to the sub-epicardium
Ischemic cardiomyopathy         Less frequent                  After ineffective endocardial                                Epicardial ablation may be required more frequently in   
                                                                                          ablation/arrhythmia recurrence                            the presence of an inferior myocardial infarction
Idiopathic VT                              Rare                                 Mapping and ablation mostly successful             Epicardial left VT origin likely if MDI ≥0.55 and VT
                                                                                          from within cardiac venous system in case        origin remote from the sinus of Valsalva
                                                                                          of epicardial origin 
ARVC/D = arrhythmogenic right ventricular cardiomyopathy/dysplasia; VT = ventricular tachycardia. 
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located next to a valve annulus.30–33 The scar area may be larger in the
epicardium than the endocardium or limited entirely to the epicardium
in some patients. Contrast-enhanced cardiac magnetic resonance
imaging of patients with dilated cardiomyopathy shows mid-wall fibrosis
in up to one third of cases, different to the subendocardial/transmural
pattern found in ischaemic cardiomyopathy.34,35 The presence of 
mid-myocardial fibrosis has been found to be predictive of an arrhythmic
event.34 Intracardiac echocardiography can identify increased
echogenicity in the lateral wall of the left ventricle (LV) of some patients
with dilated cardiomyopathy.36 This increased echogenicity was found to
correspond to abnormal epicardial substrate and therefore may guide
an epicardial approach. As discussed above, the extent of the
epicardial substrate in patients with dilated cardiomyopathy can also
be estimated with endocardial unipolar voltage mapping.17 
Combined endo- and epicardial ablation in patients with dilated
cardiomyopathy and VT results in high rates of arrhythmia-free
outcomes.30,31,33 However, the patient populations in these studies are
highly selected as most had failed previous endocardial VT ablation,
favouring the presence of an epicardial circuit. Results, therefore,
cannot be generalised to all patients with dilated cardiomyopathy
and VT, although epicardial ablation should be considered in patients
with failed endocardial ablation. 
Myocarditis
Except for chagasic myocarditis, there are only a few case reports and one
study on VT ablation in patients with myocarditis. In that study, 20 patients
with active, biopsy-proven myocarditis and VT underwent endocardial VT
ablation.37 Epicardial ablation was performed during a second procedure
in six patients because of procedural failure of endocardial ablation. Two
patients (10 %) had arrhythmia recurrence during 28 months of follow-up.
In patients with active myocarditis, contrast-enhanced cardiac magnetic
resonance imaging showed a mid-wall and sub-epicardial distribution of
inflammation, which suggests that the epicardium may be an important
ablation target.38,39 However, VT will cease spontaneously during recovery
in many patients with myocarditis, therefore the current data does not
allow us to draw any conclusion about the role of epicardial ablation in this
patient population. A total of five patients with chronic myocarditis
referred at our institution for VT ablation required epicardial ablation. 
Scar area were confined to the subepicardium of the left lateral LV wall in
all and inferior wall in two of them.
Chagasic Cardiomyopathy
The method of percutaneously accessing the pericardial space for
epicardial VT ablation was first described in three patients with
chagasic cardiomyopathy.6 Using combined endo- and epicardial
access for VT ablation, the same group reported a high arrhythmia-free
success rate.40 It was later demonstrated that patients with chagasic
cardiomyopathy and VT have a two-fold greater epi- than endocardial
scar area.41 Combined epi- and endocardial substrate ablation was
very successful in reducing the number of recurrent arrhythmia 
in this study .  
Hypertrophic Cardiomyopathy
Patients with hypertrophic cardiomyopathy may have monomorphic
VT. According to published case series, epicardial substrate may be
present in up to 80 % of patients, and epicardial ablation can
terminate VT or prevent VT recurrence in a substantial number of
patients.42–44 In patients with apical hypertrophic cardiomyopathy
epicardial ablation may be especially useful.45
Brugada Syndrome
Triggers initiating polymorphic VT and ventricular fibrillation in Brugada
syndrome patients can be ablated very successfully from the
endocardium of the right ventricular outflow tract or the right ventricular
Purkinje system.46 In nine Brugada syndrome patients with recurrent
ventricular fibrillation but without frequent ventricular ectopics, mapping
studies found pathological substrate located over the anterior 
right ventricular outflow tract epicardium.47 Extensive epicardial 
ablation of this substrate rendered most patients non-inducible with
normalization of Brugada-type ECG patterns and very high long-term
arrhythmia-free success rate. 
Sarcoidosis
The first case series described results of ablation in eight patients 
with VT and sarcoidosis.48 In two patients, endocardial ablation failed
to abolish VT; subsequent epicardial mapping showed an extensive
epicardial substrate in one patient. Of note, four out of these eight
patients ultimately required heart transplantation for recurrent VT.
Another case series on nine patients with cardiac sarcoidosis
reported one patient who underwent successful epicardial ablation
after no endocardial substrate was found.49 Necropsy findings in
patients with cardiac sarcoidosis show a predilection of granulomas
to the sub-epicardium and interventricular septum.50
Coronary Heart Disease
Large, multicentre studies on the outcome of endocardial VT ablation in
patients with predominantly coronary heart disease consistently report
an arrhythmia-free success rate of approximately 50 % and a significant
reduction of the number of VT episodes in the remaining patients.3,5,51–53
Due to the myocardial vascular supply, myocardial infarction causes
sub-endocardial or transmural scars, a pattern that is also found 
on contrast-enhanced magnetic resonance imaging.35 High-density
electro-anatomical mapping studies in patients with ischaemic
cardiomyopathy report the endocardial scar area to be significantly
larger than the epicardial scar area.33,54 However, early surgical studies
already described that VT in ischaemic cardiomyopathy may involve 
the sub-endocardium and is amenable to epicardial interventions.55,56
Sosa et al. were the first to show the feasibility of epicardial ablation 
in post-infarct patients.57 Several studies have since reported good
success rates of combined endo- and epicardial ablation in patients
with ischaemic cardiomyopathy, mainly after failed endocardial VT
ablation.7–9,33 Detailed endo- and epicardial mapping of stable VT circuits
in post myocardial infarction patients revealed a putative epicardial
isthmus in a minority of them.58 The prevalence of an epicardial circuit
may be higher in patients with inferior or infero-lateral rather than
anterior myocardial infarction.1,9,59 Therefore, epicardial VT ablation in
patients with ischaemic cardiomyopathy should be considered after
failed endocardial ablation. Because ischaemic cardiomyopathy is by
far the most frequent cardiomyopathy present in patients with VT, this
patient population will also be the largest in absolute numbers in whom
an epicardial access is necessary for successful VT abolition. 
Idiopathic Ventricular Tachycardia
Up to 14 % of outflow tract VT originate from the great cardiac vein
and can be successfully ablated from within a cardiac vein or via a
direct epicardial approach.60,61 Daniels et al. described ECG characteristics
of idiopathic VT of epicardial origin, remote from the aortic sinus of
Valsalva and compared them to idiopathic outflow tract VT.16
A myocardial deflection index ≥0.55 (MDI, see Table 1) was 100 %
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sensitive and 98.7 % specific for an epicardial origin (see Table 2).
Origin of VT was perivascular in all cases and ablation was successful
in the majority, either through the coronary veins or via a direct
epicardial approach. Another group described four patients with
idiopathic epicardial VT originating from the crux of the heart.62 All
patients had a MDI ≥0.55 and ablation was successful from the
coronary veins in one and via a direct epicardial approach in two.
According to another study, the MDI had limited value for
discriminating endocardial from epicardial VT origin in sites adjacent
to the left sinus of Valsalva like the distal great cardiac vein and
anterior inter-ventricular cardiac vein.63 In patients with idiopathic VT
a perivascular origin has to be considered and mapping and ablation
from within the cardiac venous system is feasible and successful.  
Other Considerations, Contraindications 
and Complications 
In some instances, endocardial VT ablation is not possible because of
left ventricular thrombus, mechanical valves in aortic and mitral
positions, or severe peripheral artery disease that prohibits
retrograde trans-arterial access. In such cases, epicardial ablation
without simultaneous endocardial access is a possible alternative
before considering surgical options. 
Contraindications
In patients with prior pericarditis or cardiac surgery, pericardial
adhesions that prohibit epicardial access or constrain catheter
manoeuvrability can be anticipated and we prefer not to obtain
percutaneous epicardial access in these patients.64,65 Similarly,
pericardial adhesions may be present after prior epicardial ablation
with subsequent pericarditis.64,66 Although other groups have
reported that these pericardial adhesions can be dissected with the
ablation catheter and a steerable sheath, we are very cautious
about this as it may have devastating consequences.65,66 If epicardial
access cannot be obtained or in case of adhesions, a direct surgical
epicardial approach creating a sub-xiphoid pericardial window with
surgical dissection of pericardial adhesions is our preferred
alternative.67 Pericardial agenesis is a very rare disease precluding
epicardial access. This diagnosis may be suspected from the ECG
which shows right axis deviation and clockwise rotation of the QRS
complexes in the precordial leads as well as from the chest x-ray
which may demonstrate levo-position of the heart and elongation 
of the left heart border. Finally, the coagulation status and the
presence of antithrombotic or anticoagulant drugs should be
considered before attempting epicardial access. In the presence 
of systemic anticoagulation pericardial puncture should be postponed
if possible. 
Complications
Pericardial bleeding is the most frequent complication of pericardial
puncture and can be present to some degree in up to 30 % of
patients.1,11 Hepatic or intraabdominal bleeding may also occur after
accidental puncture of the liver or a subdiaphragmatic vessel.68 Injury
to the coronary arteries or the phrenic nerve by nearby ablation are
other well recognised complications of epicardial ablation.11,68 It is
important to remember that air in the pericardial space can increase
the defibrillation threshold and should be evacuated before
attempting defibrillation.69 Pericarditic symptoms have been reported
in up to 29 % of patients after epicardial ablation and may manifest as
major pericardial inflammatory reaction in some patients.11,68
Summary
Several clues may suggest the presence of epicardial substrate
involved in a VT circuit and help with the decision to gain pericardial
access. The most important factor is the type of cardiomyopathy. An
epicardial substrate is frequently present in cases with ARVC/D or
dilated cardiomyopathy. Electrocardiogram characteristics may have
a role, but it is important to recognise their limitations. Both interval
and morphology ECG criteria have been assessed for selected 
patient populations and morphology criteria also are site-specific.
Electrogram characteristics and endocardial maps can provide
additional evidence for the presence of epicardial substrate and
should also be considered. Finally, pericardial adhesions may be
present in patients with prior cardiac surgery or pericarditis and
prohibit percutaneous pericardial access. n
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